1,5-二氢苯并[b][1,4]二氮杂卓-2,4-二酮 | 49799-48-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 1,5-二氢苯并[b][1,4]二氮杂卓-2,4-二酮
• 英文名称: 1H-1,5-benzodiazepine-2,4(3H,5H)-dione
• 英文别名: 1,5-benzodiazepin-2,4-dione；2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine；1,5-dihydro-1,5-benzodiazepine-2,4-dione
• CAS: 49799-48-6
• 化学式: C₉H₈N₂O₂
• mdl: MFCD00464634
• 分子量: 176.175
• InChiKey: UNFHOAZOCIELCW-UHFFFAOYSA-N

物化性质

• 熔点：
  >250 °C(Solv: dimethyl sulfoxide (67-68-5); water (7732-18-5))
• 沸点：
  467.6±38.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,5-二氢苯并[b][1,4]二氮杂卓-2,4-二酮 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 硝酸 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成 N-(2''-hydroxyl-3'',5''-dibromophenyl-methylene-yl)-4'-iminobenzol[1',2'-d]-1,4-diazacycloheptane[2,3-d]-5,7-dione
  参考文献：
  名称：

  Biological Interaction Between Copper(II) Complex and Nucleosides

  摘要：

  我们设计并合成了一种基于 7 元酰胺循环的铜配位复合物。通过紫外可见光谱和晶体结构研究了它与各种核苷（5-二磷酸鸟苷（GDP）、5-二磷酸尿苷（UDP）、5-二磷酸肌苷（IDP）和 5-三磷酸鸟苷（GTP））的结合特性。结果表明，在所研究的核苷类化合物中，该化合物在水溶液中与 5-三磷酸鸟苷的结合能力最强。主客体之间的相互作用源于氢键和 p-p-staking，主客体结合能力取决于核苷的链长。此外，该化合物还可用于标记核苷。

  DOI：

  10.14233/ajchem.2014.16964
• 作为产物：
  描述：

  邻苯二胺 在 丙二酸 作用下， 生成 1,5-二氢苯并[b][1,4]二氮杂卓-2,4-二酮
  参考文献：
  名称：

  Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。

  公开号：

  US06528505B1

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF CLOBAZAM AND ITS INTERMEDIATE<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION DE CLOBAZAM ET SON INTERMÉDIAIRE
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2016151464A1

  公开（公告）日：2016-09-29

  The present invention provides an improved process for the preparation of 8-chloro-1-phenyl- 1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione (hereafter referred to as the compound (IV)), which is useful as a key intermediate for the synthesis of Clobazam (referred to as the compound (I)) 7-chloro-1-methyl-5-phenyl-1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione. The process of the present invention further involves transformation of the compound (IV) into Clobazam (I), comprising (a) reacting the compound (II) (as described herein) with monoalkyl malonate in the presence of a coupling agent to obtain the compound (III) (as described herein); followed by the cyclization using a base; (b) reacting the compound-IV (as described herein) obtained from step (a) with methylating agent. The process of the present invention involves formation of novel intermediates methyl 3-((4- chloro-2-(phenylamino)phenyl)amino)-3-oxopropanoate (IlIa) and 3-((4-chloro-2- (phenylamino)phenyl)amino)-3-oxopropanoic acid (V).

  本发明提供了一种改进的制备8-氯-1-苯基-1H-苯并[b][1,4]二氮杂环-2,4(3H,5H)-二酮（以下简称为化合物（IV））的过程，该过程用作合成氯硝安（简称为化合物（I））7-氯-1-甲基-5-苯基-1H-苯并[b][1,4]二氮杂环-2,4(3H,5H)-二酮的关键中间体。本发明的过程还涉及将化合物（IV）转化为氯硝安（I），包括(a)在偶联剂存在下将化合物（II）（如本文所述）与单烷基马隆酸酯反应，以获得化合物（III）（如本文所述）；随后使用碱进行环化；(b)将从步骤(a)中获得的化合物-IV（如本文所述）与甲基化试剂反应。本发明的过程涉及新型中间体甲基3-((4-氯-2-(苯胺基)苯基)氨基)-3-氧代丙酸酯（IlIa）和3-((4-氯-2-(苯胺基)苯基)氨基)-3-氧代丙酸（V）的形成。
• CCK or gastrin modulating benzo \x9bb!\x9b1,4! diazepines derivatives
  申请人：Glaxo Wellcome Inc.

  公开号：US05859007A1

  公开（公告）日：1999-01-12

  Benzo\x9bb!\x9b1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.6 R.sup.7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R.sup.8 and R.sup.9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

  以下是您提供的化学公式和描述的中文翻译： 本专利涉及1,4-苯并二氮杂卓化合物，其分子式为(I)，其中R1选自C1-C6烷基、C3-C6环烷基、苯基或取代苯基；R2选自C3-C6烷基、C3-C6环烷基、C3-C6烯基、苄基、苯基C1-C3烷基或取代苯基；或NR1R2共同形成1,2,3,4-四氢喹啉或苯并氮卓环，且单独或同时以C1-6烷基、C1-6烷氧基或卤素取代基进行单、双或三取代；p为0或1的整数；q为0或1的整数；r为0或1的整数；t为0或1的整数，条件是当r为0时，t也为0；R3、R5和R6独立地为氢或C1-6烷基；R4为C1-6烷基或C1-6烯基；R7选自氢、C1-6烷基、C1-6环烷基、C1-6烯基、苯基、取代苯基、萘基、杂芳基、取代杂芳基、双环杂芳基或取代双环杂芳基；或NR6R7共同形成一个由1,2,3或4个N、S或O杂原子隔断的饱和的5,6或7元环，条件是任意两个O或S原子不得相互连接；m为0、1、2、3或4的整数；R8和R9选自多种取代基；Z为氢或卤素；本专利还包括新颖的中间体、用于治疗肥胖、胆囊淤滞、胰腺分泌障碍的药物组合物，以及用于治疗这些疾病的方法和制备公式(I)化合物的方法。
• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Athena Neurosciences, Inc.

  公开号：US06506782B1

  公开（公告）日：2003-01-14

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06509331B1

  公开（公告）日：2003-01-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。